Have a feature idea you'd love to see implemented?
Let us know!
PASG Passage BIO Inc
Price (delayed)
$0.536
Market cap
$33.11M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.17
Enterprise value
$26.63M
Passage Bio, has the mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with
Highlights
The EPS has grown by 43% YoY and by 13% from the previous quarter
The net income is up by 39% year-on-year and by 10% since the previous quarter
The equity has contracted by 42% YoY and by 20% from the previous quarter
The quick ratio has decreased by 33% QoQ and by 25% YoY
Key stats
What are the main financial stats of PASG
Market
Valuations
Earnings
Shares outstanding
61.77M
Market cap
$33.11M
Enterprise value
$26.63M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.46
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$68.8M
EBITDA
-$65.63M
Free cash flow
-$59.06M
Per share
Balance sheet
Liquidity
EPS
-$1.17
Free cash flow per share
-$0.96
Book value per share
$1.18
Revenue per share
$0
TBVPS
$1.81
Total assets
$111.75M
Total liabilities
$39.04M
Debt
$25.82M
Equity
$72.72M
Working capital
$70.27M
Debt to equity
0.36
Current ratio
5.15
Quick ratio
5
Net debt/EBITDA
0.1
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-52.1%
Return on equity
-72.5%
Return on invested capital
-60%
Return on capital employed
-72.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PASG stock price
How has the Passage BIO stock price performed over time
Intraday
4.34%
1 week
-9.18%
1 month
-8.92%
1 year
-13.55%
YTD
-46.93%
QTD
-23.43%
Financial performance
How have Passage BIO's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$68.8M
Net income
-$68.8M
Gross margin
N/A
Net margin
N/A
The operating income is up by 39% year-on-year and by 10% since the previous quarter
The net income is up by 39% year-on-year and by 10% since the previous quarter
Growth
What is Passage BIO's growth rate over time
Valuation
What is Passage BIO stock price valuation
P/E
N/A
P/B
0.46
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 43% YoY and by 13% from the previous quarter
The stock's price to book (P/B) is 62% less than its 5-year quarterly average of 1.2 and 23% less than its last 4 quarters average of 0.6
The equity has contracted by 42% YoY and by 20% from the previous quarter
Efficiency
How efficient is Passage BIO business performance
The company's return on equity fell by 4.6% YoY and by 2.5% QoQ
PASG's return on assets is up by 4.9% year-on-year
The ROIC has grown by 3.8% YoY
Dividends
What is PASG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PASG.
Financial health
How did Passage BIO financials performed over time
Passage BIO's total assets is 186% more than its total liabilities
Passage BIO's total assets has decreased by 34% YoY and by 11% from the previous quarter
The quick ratio has decreased by 33% QoQ and by 25% YoY
The debt is 64% less than the equity
The debt to equity has soared by 71% YoY and by 24% from the previous quarter
The equity has contracted by 42% YoY and by 20% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.